Aldeyra Therapeutics Announces Board and Executive Changes

Ticker: ALDX · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1341235

Aldeyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAldeyra Therapeutics, INC. (ALDX)
Form Type8-K
Filed DateApr 17, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: ALDX

TL;DR

Aldeyra shakes up board and exec pay on 4/17.

AI Summary

Aldeyra Therapeutics, Inc. announced on April 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial priorities.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategic direction and operational stability.

Key Players & Entities

FAQ

What specific roles have been affected by the departures of officers or directors?

The filing indicates "Departure of Directors or Certain Officers" as an item, but does not specify the exact roles in the provided text.

Who are the newly elected directors?

The filing lists "Election of Directors" as an item, but the names of the newly elected directors are not provided in the text.

What are the details of the compensatory arrangements for certain officers?

The filing mentions "Compensatory Arrangements of Certain Officers" but does not provide specific details on these arrangements in the text.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is dated April 17, 2025.

What is Aldeyra Therapeutics, Inc.'s SIC code?

Aldeyra Therapeutics, Inc.'s Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing